RxDoctor Payments Data

Ajaya Tummala, MD

Cardiovascular Disease · Shreveport, LANPI 1487628194

Payments from drug & device makers

$1,636in general payments, 2019–2025

Across 85 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$236
  • E.r. Squibb & Sons, L.L.C.$189
  • Abbott$152
  • Pfizer$140
  • Novartis$132
  • Sanofi$118
  • plus $670 from 19 others

What the payments were for

  • Food & beverage$1,636100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,636 in reported general payments places this provider in the 35th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$150,987
Medicare patients
758
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$328,430
EntrestoSacubitril/Valsartan258$273,462
JardianceEmpagliflozin253$226,074
XareltoRivaroxaban127$111,400
FarxigaDapagliflozin Propanediol76$65,084
Repatha SureclickEvolocumab20$18,888
BrilintaTicagrelor11$11,522
Repatha SyringeEvolocumab13$8,007
Metoprolol Succinate662$7,862
Rosuvastatin Calcium527$7,031
Combivent RespimatIpratropium/Albuterol Sulfate14$6,506
Prasugrel Hcl68$6,123
ClopidogrelClopidogrel Bisulfate333$3,606
Ranolazine ErRanolazine19$3,531
Losartan Potassium281$3,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$328,430368 claims
NovartisEntresto$132$273,462258 claims
Johnson & JohnsonXarelto$11$111,400127 claims
AstraZenecaFarxiga, Brilinta$13$76,60687 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →